BioCentury
ARTICLE | Clinical News

AIC Phase II data for Dynavax

March 20, 2001 8:00 AM UTC

Dynavax (Berkeley, Calif.) reported that in a French Phase II trial of its AIC anti-allergy vaccine in 27 adults with ragweed allergies, a six-injection dose-ranging regimen was safe and well-tolerate...